RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'

Follow Drugslib on

By Andria Park Huynh HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, May 8, 2026 — A new federal initiative aims to curb "overprescribing" of psychiatric medications while emphasizing holistic care.

“Today, we take clear and decisive action to confront our nation’s mental health crisis by addressing the overuse of psychiatric medications — especially among children,” U.S. Health Secretary Robert F. Kennedy Jr. said Monday at a summit on mental health and overmedicalization.

“We will support patient autonomy, require informed consent and shared decision-making and shift the standard of care toward prevention, transparency and a more holistic approach to mental health,” he said.

Kennedy’s new action plan — announced at a Make America Healthy Again (MAHA) Institute summit on mental health and overmedicalization — follows a recent push by mental health professionals for more research on discontinuation of psychiatric medications, according to CNN.

Psychiatric medications, particularly antidepressants, have been one of Kennedy's targets since taking office last year.

The secretary has claimed that these drugs are overprescribed and may be linked to mass violence and shootings as well as serious risks to developing fetuses in pregnant women, according to CNN.

While psychiatric medications carry some slight risks, the U.S. Food and Drug Administration (FDA) deems them safe and effective for mental health disorders including depression, anxiety, eating disorders, substance use disorder and obsessive-compulsive disorder.

Psychiatric professionals generally welcomed Kennedy’s announcement, while raising concerns about the emphasis on overprescribing amid broader issues with access to mental healthcare, CNN reported.

One expert said the plan fails to consider current barriers in patient care.

"This oversimplification of our mental health does not take into account things like persistent workforce shortages, limited psychiatric beds, inadequate visit time, barriers to psychotherapy and social support, and insufficient integration of psychiatric expertise in primary care," said Dr. Theresa Miskimen Rivera, president of the American Psychiatric Association, which supports the administration’s plans for further investment, research and clinical training. She is a clinical professor of psychiatry at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey.

Another expert noted that in many instances, certain medications, antidepressants included, can be lifesaving despite risks.

“As with all areas of medicine, we should be concerned about both overprescribing and underprescribing,” Dr. Jonathan Alpert, chair of psychiatry and behavioral sciences at Montefiore Medical Center in New York City, told CNN.

“In some instances, antibiotics or diabetes medications are overprescribed and cause unnecessary side effects, cost and other harms," he added. "In many other instances, they can be lifesaving. So too with psychiatric medications such as antidepressants or antipsychotics."

As far as the new plan goes, HHS agencies will aim to work together to “evaluate prescription patterns for psychiatric medications, their benefits and potential harms, and elevate the role of nonmedication treatments and scalable, evidence-based solutions to improve mental health,” the department’s news release said.

This will include education and outreach, program and policy actions, as well as initiatives to bridge the gap between research and real-world application, the release said.

Sources

  • U.S. Department of Health and Human Services, news release May 4, 2026
  • CNN, May 5, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-05-09 02:11

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords